Injection De Trumab 440 Mg

Injection de Trumab 440 mg is a pharmaceutical preparation containing Trastuzumab as its active ingredient. Trastuzumab is a targeted therapy, specifically a monoclonal antibody, designed to treat certain types of cancer. It works by selectively binding to the HER2 protein, which is overexpressed in some cancer cells, particularly in certain types of breast cancer and gastric cancer. By attaching to HER2, Trumab inhibits the growth and proliferation of these cancer cells.

This injection is indicated for the treatment of HER2-positive breast cancer, both in its early stages and in metastatic settings. It is also used for HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. The dosage and administration of Injection de Trumab 440 mg should be strictly determined by a qualified healthcare professional based on the patient’s condition and response to treatment. Common side effects may include infusion-related reactions, fatigue, nausea, vomiting, and cardiac toxicity. Patients should be monitored for potential side effects, especially cardiac function, throughout the treatment course.

Storage instructions for Injection de Trumab 440 mg typically involve refrigeration at 2°C to 8°C (36°F to 46°F). It should be protected from light and should not be frozen. Any unused portion of the reconstituted solution should be discarded. Always consult your doctor or pharmacist for specific storage and administration guidelines.